Stem cell therapy for cardiac disease

Bernstein, Harold S.; Srivastava, Deepak

doi:10.1038/pr.2011.61

Cited by 108 publications

(92 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Thus, new therapies must be developed to overcome the poor prognosis of MI. Several alternative strategies based on drug treatments, 32 injections of stem cells or proteins, 4,5 surgical interventions 33 and epicardial restraint devices 34 have been used to regenerate the infarcted heart. The effects of liraglutide have been shown to be beneficial for the treatment of MI.…”

Section: Discussionmentioning

confidence: 99%

“…2 Some accepted treatment methods for MI still have several limitations. 3 Thus, several new therapies have been developed to regenerate the infarcted myocardium, such as the administration of stem cells, 4 growth factors or proteins 5 or gene therapy. 6 Liraglutide has initially been approved for clinical use as a treatment for type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Qi¹,

Lü

Li³

et al. 2017

IJN

View full text Add to dashboard Cite

The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic- co -glycolic acid)–poly(ethylene glycol) (PLGA–PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA–PEG nanoparticles (NPs) have been shown to efficiently load liraglutide and release bioactive liraglutide in a sustained manner. For in vitro test, the released liraglutide retained bioactivity, as measured by its ability to activate liraglutide signaling pathways. Next, we compared the effects of an intramyocardial injection of saline, empty NPs, free liraglutide and NP-liraglutide in a rat model of MI. NPs were detected in the myocardium for up to 4 weeks. More importantly, an intramyocardial injection of NP-liraglutide was sufficient to improve cardiac function ( P <0.05), attenuate the infarct size ( P <0.05), preserve wall thickness ( P <0.05), promote angiogenesis ( P <0.05) and prevent cardiomyocyte apoptosis ( P <0.05) at 4 weeks after injection without affecting glucose levels. The local, controlled, intramyocardial delivery of NP-liraglutide represents an effective and promising strategy for the treatment of MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Qi¹,

Lü

Li³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Using this mild protocol it is possible obtain a cell population with 96% c-Kit positive cells [15]. This population is also positive to Sca-1 and MDR-1 (unpublished data), as described by Srivastava and colleagues [16] in a recent paper. Their differentiation potential have been evaluated by many research groups [9,[12][13][14], but the complete differentiation and creation of a small piece of myocardium have never been demonstrated both in vivo and in vitro.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA and Cardiac Stem Cell Therapy

Serradifalco

Zummo

Felice

2012

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Cardiac Progenitor Cells (CPCs) are multipotent cells of the myocardium. They are located inside niches of the heart muscle, can be isolated, characterized and used for cardiac regeneration in stem cell therapy. Actually, CPCs may be isolated by tissue digestion with or without cell sorting, but it is difficult to achieve the maximum level of differentiation when these cells are implanted into a damaged myocardium.The knowledge recently acquired on small molecules of non-coding RNAs, microRNA (miRNA), may improve the use of these cells in stem cell therapy. In fact, these small molecules may be attached to devices or adminstered as they are or in combination with nanoparticles in order to drive the correct differentiation of stem cells. Regarding heart regeneration, we can acquire knowledge from the role of miRNAs in heart development and use it to reprogram CPCs to gain the correct three-dimensional structure of the cardiac muscle.

show abstract

“…Cardiac stem cells (CSCs) are widely investigated in the treatment of cardiovascular disorders (reviewed in Bernstein and Srivastava (2012)). The discovery of c-kit + CSCs followed the identification of other CSCs, including epicardial progenitors, Isl1 + cardiovascular progenitors, side population progenitors, Sca1 + progenitors, heterogeneous progenitors containing cardiospheres, and cardiac mesenchymal stem cells (Beltrami et al, 2003;Oh et al, 2003;Messina et al, 2004;Smith et al, 2007;Bu et al, 2009;Chong et al, 2011).…”

Section: Cardiac Stem Cells and Induced Cardiomyocytesmentioning

confidence: 99%

Underlying mechanisms and prospects of heart regeneration

Aslan¹,

Misir²,

Kocabaş³

2016

Turk J Biol

View full text Add to dashboard Cite

Using electron microscopy in 1974, Oberpriler et al. (1974 demonstrated the prospect of cardiac regeneration in newts. Later, Witman et al. (2011) reported that the adult newt is able to completely regenerate its heart after a basal resection (Witman et al., 2011). Zebrafish (Danio rerio) is a tropical freshwater fish Abstract: Findings in the last decade suggest that there is a considerable amount of cardiomyocyte turnover in the human heart throughout life, albeit not sufficient for heart regeneration following myocardial infarctions. Only a few species are known to be remarkably efficient in cardiac regeneration. They restore lost cardiomyocytes via a process of cardiomyocyte dedifferentiation, which is followed by robust proliferation of cardiomyocytes and incorporation into the myocardium. Similarly, neonatal mice have been recently shown to regenerate their heart following myocardial injuries. Studies with a neonatal cardiac regeneration mouse model suggest that the major source of new cardiomyocytes is likely to be of cardiomyocyte origin, with the possibility of involvement of cardiac stem cells. To this end, numerous studies have been conducted on the induction of cardiac regeneration to shed light on the underlying mechanisms. This review covers studies on the renewal of cardiomyocytes, the utilization of stem cells in myocardial therapies, and their future applications.

show abstract

Stem cell therapy for cardiac disease

Cited by 108 publications

References 107 publications

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

MicroRNA and Cardiac Stem Cell Therapy

Underlying mechanisms and prospects of heart regeneration

Contact Info

Product

Resources

About